Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Ventyx Biosciences, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/11/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/10/2023 144 Form 144 - Report of proposed sale of securities:
10/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis",
"Corporate Presentation"
10/06/2023 4 Mohan Raju (CEO) has filed a Form 4 on Ventyx Biosciences, Inc.
Txns: Sold 30,000 shares @ $29.1077, valued at $873.2k
Exercised 30,000 options to buy @ $8.04, valued at $241.2k
10/05/2023 144 Form 144 - Report of proposed sale of securities:
10/04/2023 4 Krueger Christopher W (Chief Business Officer) has filed a Form 4 on Ventyx Biosciences, Inc.
Txns: Sold 14,006 shares @ $29.9291, valued at $419.2k
Sold 994 shares @ $30.6959, valued at $30.5k
Exercised 15,000 options to buy @ $8.04, valued at $120.6k
10/04/2023 4 Nuss John (Chief Scientific Officer) has filed a Form 4 on Ventyx Biosciences, Inc.
Txns: Sold 9,277 shares @ $29.937, valued at $277.7k
Sold 723 shares @ $30.7155, valued at $22.2k
Exercised 1,401 options to buy @ $0.2, valued at $280.2
Exercised 7,972 options to buy @ $3.54, valued at $28.2k
Exercised 627 options to buy @ $8.04, valued at $5k
10/03/2023 144 Form 144 - Report of proposed sale of securities:
10/03/2023 144 Form 144 - Report of proposed sale of securities:
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Ventyx Biosciences, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss Three months ended June 30, Six months ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 48,560 $ 14,676 $ 83,997 $ 32,085 General and administrative 8,585 5,722 15,700 11,060 Total operating expenses 57,145 20,398 99,697 43,145 Loss from operations Other expense: Interest income Other expense 5 6 79 Total other expense Net loss $ $ $ $ Unrealized gain on marketable securities 352 Foreign currency translation 38 61 Comprehensive loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted average common shares outstanding, basic and diluted 58,556,529 50,848,391 58,100,261 50,717,548 Ventyx Biosciences, Inc. Selected Condensed Consolidated Balance S..."
08/08/2023 4 Sandborn William J. (See Remarks) has filed a Form 4 on Ventyx Biosciences, Inc.
Txns: Sold 2,086 shares @ $32.6852, valued at $68.2k
Sold 1,408 shares @ $33.1167, valued at $46.6k
08/08/2023 4 Mohan Raju (CEO) has filed a Form 4 on Ventyx Biosciences, Inc.
Txns: Sold 20,225 shares @ $33.2017, valued at $671.5k
Sold 8,898 shares @ $34.0938, valued at $303.4k
Sold 877 shares @ $35.005, valued at $30.7k
Exercised 30,000 options to buy @ $8.04, valued at $241.2k
08/08/2023 144 Form 144 - Report of proposed sale of securities:
08/07/2023 144 Form 144 - Report of proposed sale of securities:
08/04/2023 4 Nuss John (Chief Scientific Officer) has filed a Form 4 on Ventyx Biosciences, Inc.
Txns: Sold 8,887 shares @ $35.5587, valued at $316k
Sold 1,113 shares @ $35.9171, valued at $40k
Exercised 10,000 options to buy @ $0.2, valued at $2k
08/04/2023 4 Krueger Christopher W (Chief Business Officer) has filed a Form 4 on Ventyx Biosciences, Inc.
Txns: Sold 13,300 shares @ $35.5452, valued at $472.8k
Sold 1,700 shares @ $35.9094, valued at $61k
Exercised 15,000 options to buy @ $8.04, valued at $120.6k
08/04/2023 4/A Krueger Christopher W (Chief Business Officer) has filed a Form 4 on Ventyx Biosciences, Inc.
Txns: Exercised 1,089 options to buy @ $8.04, valued at $8.8k
Exercised 13,911 options to buy @ $0.2, valued at $2.8k
08/03/2023 144 Form 144 - Report of proposed sale of securities:
08/03/2023 144 Form 144 - Report of proposed sale of securities:
08/01/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/01/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/01/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/31/2023 144 Form 144 - Report of proposed sale of securities:
07/26/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/25/2023 8-K Quarterly results
07/25/2023 144 Form 144 - Report of proposed sale of securities:
07/19/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
07/19/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
07/19/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
07/13/2023 4 NSV Partners III LP (10% Owner) has filed a Form 4 on Ventyx Biosciences, Inc.
Txns: Sold 28,646 shares @ $37.5414, valued at $1.1M
Sold 3,275 shares @ $37.6242, valued at $123.2k
07/13/2023 4 Subramaniam Somu (10% Owner) has filed a Form 4 on Ventyx Biosciences, Inc.
Txns: Sold 28,646 shares @ $37.5414, valued at $1.1M
Sold 3,275 shares @ $37.6242, valued at $123.2k
07/11/2023 4 Subramaniam Somu (10% Owner) has filed a Form 4 on Ventyx Biosciences, Inc.
Txns: Sold 75,686 shares @ $34.9879, valued at $2.6M
Sold 20,718 shares @ $35.8225, valued at $742.2k
Sold 3,596 shares @ $36.9277, valued at $132.8k
Disposed of 1,030,341 shares @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy